Skip to main content
. 2019 Nov 6;39(45):8885–8899. doi: 10.1523/JNEUROSCI.2832-18.2019

Figure 2.

Figure 2.

Sema3A negatively regulates CS collateral formation in vivo. A–R, Immunostaining of P14 lumbar spinal cord sections from AAV8-LacZ injected (A–C; control) mice and AAV8-LacZ/Sema3A injected mice (D–F) using antibodies targeting GFP (green) and LacZ (red). Regions with a high-power view are indicated by red squares. G–R, High-power views of boxed areas from AAV8-LacZ-injected (G–L; control) and AAV8-LacZ/Sema3A-injected (M–R) mice. S, Quantification of axon collateral intensities, showing significant reductions of axon collaterals in AAV8-LacZ/Sema3A-injected mice compared with AAV8-LacZ-injected mice in the dorsal (p = 0.0023) and medial (p = 0.0041) but not ventral (p = 0.2642) regions of the lumbar spinal cord. Scale bars: F, 100 μm; R, 20 μm. **P < 0.01, n.s. = not significant.